• ZyVersa Advances Development of Inflammasome Inhibitor Candidate americanpharmaceuticalreview
    September 06, 2019
    ZyVersa announced advancements in development of our lead inflammasome inhibitor candidate, IC 100. IC 100 is a novel monoclonal antibody that inhibits the ASC component of multiple types of inflammasomes...
PharmaSources Customer Service